Myasthenia gravis is an extremely polymorphic disorder. It can be separated into individual types. In addition, neuromuscular transmission can be affected by genetic and toxic factors.
Classification of neuromuscular transmission disorders based on pathogenesis
|
immune mediated
|
presynaptic |
|
|
postsynaptic |
||
|
nonimmune
|
presynaptic and postsynaptic |
|
|
|
Based on age
|
immune mediated
|
|
|
|
|
|
adult myasthenia
|
|
|
myasthenia in elderely |
|
|
genenetics mediated
|
Based on antibody status
|
AChR+ |
85% |
|
|
7% |
|
Ab neg
|
8% |
Based on antibody status
|
hyperplasia |
65% |
|
atrophy |
20% |
|
10 - 15% |
Based on disease severity and the extent of neuromuscular weakness
The fluctuation extent and the variable predominance of the muscle group involved, makes it extremely difficult to classify the patients with MG. Most existing classifications are modifications of Osserman’s original scheme. The most widely accepted classification of myasthenia gravis is the Myasthenia Gravis Foundation of America Clinical Classification (MGFA). More precise is Quantitative MG Score (QMG) for disease severity, that is quite complicated and is used in the objective evaluation of therapy for MG.
There is The Myasthenia gravis composite designed by Sanders in 2008, considering factors such as disease severity according to the extent of weakness in individual muscles groups.
There is more classification available for scientist research purposes – such as Quality of life scale, The Postintervention Status, and others.